Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial
High-dose influenza vaccines provide better protection against influenza infection than standard-dose in persons aged 65 years and above.
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change
Organismal ageing is associated with many physiological changes, including differences in the immune system of most animals.
Using correlates to accelerate vaccinology
Correlates and surrogates of desired outcomes are valuable but have limitations
Digital intervention increases influenza vaccination rates for people with diabetes in a decentralized randomized trial